ClinicalTrials.gg
Enrolling by invitationNCT07439822ENDOALF-TRUpdated Feb 27, 2026

Usefulness of High-flow Oxygen Therapy of Patients at Risk of Hypoxemia Undergoing Digestive Endoscopy Under Deep Sedation

A Phase 4 interventional study of High-flow medical oxygen insufflation and Low-flow medical oxygen insufflation in Hypoxemia During Surgery, sponsored by Outcomes'10. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Outcomes'10 · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hypoxia with a site in Spain — 11 open to participants now, 11 under way, 5 of them phase 3. Hypoxia · Spain.

Planned enrollment
2nd of 25
326 · median 60
Started
2026
with 1 other
Phase 4
Only one
of the 31
Primary completion
2026-10
later than 7 of 10 live
Registered
29th of 31
by date

Among the 31 studies in Hypoxia with a site in Spain, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 4, reaches primary completion later than 7 of the 10 other live ones, and was the 29th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

11 of the 31 studies in Hypoxia with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hypoxia with a site in Spain, or all of them as a file.
02

Study summary

The study investigates the use of high-flow oxygen therapy devices in patients at higher risk of complications during sedated digestive endoscopies. Sedation controlled by the endoscopist improves patient tolerance and facilitates higher-quality procedures, but it can have side effects such as hypoxemia or respiratory depression, especially in patients with sleep apnea, obesity, lung diseases, those over 60 years old, or with a history of sedation complications. While preventive measures, such as oxygen administration, are taken, the study aims to compare the effectiveness of new high-flow oxygen therapy devices with conventional nasal cannulas to improve safety during endoscopies.

03

Conditions studied

  • Hypoxemia During Surgery

Browse trials for

Keywords

  • HIGH-FLOW OXYGEN
  • SEDATION
  • HYPOXEMIA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be ≥ 18 years old
  • Sign the
  • Obesity ( ≥ 30 kg/m²)
  • Stable pulmonary disease (no hospitalization in the last 6 months)
  • Stable heart failure (no hospitalization in the last 6 months)
  • Diagnosed or suspected obstructive sleep apnea with a score ≥ 3 on the STOP-Bang scale (APPENDIX II)
  • History of sedation-related complications in a previous ESP.

Exclusion criteria

Exclusion Criteria:

  • patients
  • Worsening heart failure at the time of the endoscopy or unstable (hospitalized \< 6 months)
  • Worsening respiratory disease at the time of the endoscopy or unstable (hospitalized \< 6 months)
  • Pregnant women
  • Use of home oxygen therapy
  • Patients with orotracheal intubation
  • Tracheostomized patients
  • Patients allergic to or unable to use propofol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
326 participants (estimated)

Study arms

  • Active comparator
    Low-flow medical oxygen insufflation

    Low-flow medical oxygen insufflation

    Drug: Low-flow medical oxygen insufflation

  • Experimental
    High-flow medical oxygen insufflation

    High-flow medical oxygen insufflation

    Drug: High-flow medical oxygen insufflation

Interventions

  • DrugHigh-flow medical oxygen insufflation

    High-flow medical oxygen insufflation

  • DrugLow-flow medical oxygen insufflation

    Low-flow medical oxygen insufflation

06

What researchers measure

Primary outcomes

  1. Number of episodes of hypoxemia

    The number of hypoxemia episodes per procedure

    Time frame: Periprocedural

  2. Severity of episode of hypoxemia pO2 value

    Severity of episode of hypoxemia (pO2 90- 80%) - (pO2 \<80%)

    Time frame: Periprocedural

  3. Duration of episode of hypoxemia (in seconds)

    Duration of episode of hypoxemia (in seconds)

    Time frame: Periprocedural

Secondary outcomes

  1. Sex (Demographic and explanatory factors)

    Sex (Demographic and explanatory factors)

    Time frame: Periprocedural

  2. Age (Demographic and explanatory factors)

    Age (Demographic and explanatory factors)

    Time frame: Periprocedural

  3. Body mass index (Demographic and explanatory factors)

    Body mass index (Demographic and explanatory factors)

    Time frame: Periprocedural

  4. Demographic and explanatory factors

    anesthetic risk classification: ASA physical status classification Obstructive Sleep Apnea (OSA) or suspected OSA based on the STOP-Bang questionnaire Chronic respiratory disease Chronic heart disease Chronic use of sedative medications History of prior respiratory complication during an endoscopic sedation procedure (ESP)

    Time frame: Periprocedural

  5. Medical History Demographic and explanatory factors

    Medical History Demographic and explanatory factors

    Time frame: Periprocedural

  6. Type of Medication and treatment used (Demographic and explanatory factors)

    Type of Medication and treatment used (Demographic and explanatory factors)

    Time frame: Periprocedural

  7. Demographic and explanatory factors

    Duration of diagnostic/ therapeutic endoscopic Procedure

    Time frame: Periprocedural

  8. Variable results

    value of baseline pO2

    Time frame: Periprocedural

  9. Variable results

    Complications and Clinical Events

    Time frame: Periprocedural

  10. Length of stay at recovery room and post-procedure (Variable results)

    Length of stay at recovery room and post-procedure

    Time frame: Periprocedural

  11. pO2 value (Variable results)

    lowest pO2 value during the procedure

    Time frame: Periprocedural

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The data will be pseudonymized to ensure privacy and will only be accessible to the research team directly involved in the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Oct 2026, 7 months later.

Of 17 phase 4 interventional studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 27, 2026
StartEst.
Mar 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439822
Lead sponsor
Outcomes'10
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion